Nektar Therapeutics

Nektar Therapeutics's next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Nektar Therapeutics has 34.13M shares outstanding.

As of June 30, 2026, Nektar Therapeutics maintains a current ratio of 10.42, meaning it holds 10.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 8.70, indicating elevated leverage, while an interest coverage ratio of -4.52 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -24.12, reflecting losses generated across the asset base. The company generates approximately 764,508.03 in revenue per employee across its workforce of 62.50, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Nektar Therapeutics recorded 56,019.20 in income tax expense. The company reported a pretax loss of -134.02M and -137.53M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Over the twelve months ended June 30, 2026, Nektar Therapeutics generated 47.78M in revenue and converted that into -137.53M in net income, yielding earnings per share of -5.67. EBITDA reached -122.58M, while operating income came in at -114.35M.

As of June 30, 2026, Nektar Therapeutics holds 599.00M in cash and equivalents against 68.76M in total debt, resulting in a net debt position of -34.37M. Total book value stands at 790.50M, with working capital of 585.07M providing operational flexibility.

Nektar Therapeutics produced -204.63M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -213,573.20 in capital expenditures, free cash flow totaled -204.85M - equivalent to -8.44 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -239.32 and net profit margin of -287.84 provide insight into operational efficiency.

Nektar Therapeutics's most recent stock split took place on June 9, 2025 with a 15:1 split ratio.